Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70 percent of the company’s workforce, only weeks after Bristol Myers Squibb abandoned its clinical collaboration program with Nektar on bladder cancer and renal cell carcinoma.
Nektar Therapeutics said on April 14 the company had stopped all clinical trials involving the drug developer’s key cancer drug bempegaldesleukin following its failure in multiple studies, dragging Nektar shares down 23% in after-market trading.
Bristol Myers Squibb Co., in a lawsuit made public on March 17, said AstraZeneca’s cancer treatment Imfinzi violates patents related to the company’s blockbuster cancer drug Opdivo.
Peregrine Market Access, a leading life science commercialization partner, was selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria. The breakthrough bladder cancer diagnostic test Oncuria is being developed to aid in detection, therapy choice, and disease monitoring. Under a multiyear, multimillion dollar agreement, Peregrine Market Access will lead the U.S. launch of Oncuria.
Germany’s Merck KGaA and Britain’s GlaxoSmithKline on Thursday ended their collaboration on the cancer treatment bintrafusp alfa, once seen as one of Merck’s most promising experimental drugs.
The U.S. Food and Drug Administration rejected Sesen Bio’s lead candidate Viceneum (oportuzumab monatox-qqrs) as a treatment for BCG-unresponsive non-muscle invasive bladder cancer.
The U.S. drug regulator declined to approve Sesen Bio Inc.’s lead therapy candidate for a type of bladder cancer, the company said on Aug. 13, sending its shares down more than 80 percent.
Opdivo Fails to Maintain Accelerated Approval in Liver CancerAccelerated Approval, Advisory Committees, Blockbusters, Clinical Trials, FDA, Hematocellular Carcinoma (HCC), Immunotherapies, Monoclonal Antibodies, Muscle-Invasive Urothelial Cancer (MIUC), Oncologic Drugs Advisory Committee (ODAC), Priority Review, R&D, Therapeutics
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee did not agree in a meeting to maintain the accelerated approval of Bristol Myers Squibb’s Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma.
AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.